Trial description:
A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2)
Contact name:
Dr Gary Doherty
Trial start date:
Friday, September 25, 2020
Trial end date:
Monday, March 23, 2026
Trial tumour type:
Lung
Show on Radiotherapy:
No
